Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
-
We report here a patient with a
2022-01-07
We report here a patient with a one-base frame-shift deletion in the PURA gene that presented an unusual phenotype including persistent hypoglycorrhachia. We propose a possible link between hypoglycorrhachia and PURA dysfunction postulating PURA as a GLUT1 regulator. We therefore hypothesize that mu
-
br Glucocorticoid receptor and metabolic syndrome GCs
2022-01-07
Glucocorticoid receptor and metabolic syndrome GCs acting through the GR regulate key enzymes of glucose metabolism in the liver, skeletal muscle, adipose tissue and the pancreas. In the liver, GCs regulate the expression of major gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase, g
-
br Acknowledgements This study was supported by National
2022-01-07
Acknowledgements This study was supported by National Institutes of Health grant (R01GM104037), VA grant (BX002741), and Rutgers Busch grant. Nuclear receptor FXR is the master regulator of bile acids homeostasis The farnesoid X receptor (FXR) belongs to a family of proteins known as nuclear
-
Lenvatinib is an orally available multi targeted
2022-01-07
Lenvatinib is an orally available, multi-targeted tyrosine kinase inhibitor against VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT [11,12]. In a recent phase III trial for patients with previously untreated uHCC (REFLECT study), lenvatinib showed statistical non-inferiority of overall survival compared to
-
The feasibility of using the Fas Fas ligand
2022-01-07
The feasibility of using the Fas/Fas ligand (FasL) system to target vascular progenitor 2801 contributing to intimal hyperplasia has been shown in many studies [[18], [19], [20], [21], [22], [23], [24]]. Fas receptor, a member of tissue necrosis factor family, is a death receptor that initiates apop
-
A few previous studies have examined Factor Xa
2022-01-07
A few previous studies have examined Factor Xa inhibitors for VTE prophylaxis in hip fracture patients. In a 2001 paper, Eriksson et al. studied 1250 patients with hip fractures that had been randomized to either postoperative Factor Xa inhibitor or enoxaparin [13]. Each patient received bilateral v
-
During the activation of the
2022-01-07
During the activation of the coagulation cascade, factor Xa (FXa) forms a complex with activated factor V and calcium bromocriptine mesylate sale on the surface of platelet membrane (so called prothrombinase complex) and converts prothrombin to thrombin [5], [6]. Selective FXa inhibitors do not dire
-
Syt itself does not catalyze lipid
2022-01-07
Syt1 itself does not catalyze lipid mixing and membrane fusion. Rather, the pairing of vesicular and target membrane SNAREs into complexes serves to pull bilayers together to drive fusion; Ca•syt1 accelerates these fusion reactions so that they occur on rapid timescales in a manner that is precisel
-
In addition to indoles two additional
2022-01-07
In addition to indoles –, two additional structural variants were synthesized to explore the synthetic flexibility and structure–activity relationships of this system. The first of these was the homologation of the acetic Cyt387 side chain to prepare compound (). The extension of the chain was exp
-
br To explore further the functional impact of
2022-01-07
To explore further the functional impact of the similarity of the UTY and KDM6A proteins, the FANTOM5 human dataset was analysed to determine whether or not the genes were expressed at the same time in the same tissues (which would suggest that they are controlled by the same regulators) or with o
-
Several mechanisms have been suggested to
2022-01-07
Several mechanisms have been suggested to underline the release of signalling molecules from astrocytes: reverse operation of glutamate transporters, volume-regulated anion channels, gap-junctional hemi channels, diffusional release through purinergic receptors and Ca2+-dependent exocytosis [2], [15
-
Mitochondrial binding by HK prevents mortality by
2022-01-07
Mitochondrial binding by HK prevents mortality by inhibiting pro-apoptotic factor (Bcl-2 family)-mediated opening of the mitochondrial permeability transition pore (mPTP) (Arora and Pedersen, 1988, Calmettes et al., 2016, Kodde et al., 2007, Pedersen et al., 2002, Rosano, 2011, Schindler and Foley,
-
Level of CD and other blood parameters in patients before
2022-01-06
Level of CD4 and other blood parameters in patients before and after intervention are presented in Table 2. The mean of the CD4+ level before treatment in the intervention and placebo groups was 161.5 ± 291.1 and 159.9 ± 337.4, respectively (P = 0.232), which increased after treatment in both groups
-
Our results indicate that abcb is
2022-01-06
Our results indicate that abcb5 is likely to be a XT in zebrafish ionocytes, although, like renal cells, the phenotypes observed likely arise from the action of multiple transporters. Zebrafish lack an abcb1 ortholog, and abcb4 and abcb5 have been identified as the P-glycoproteins in zebrafish (Fisc
-
As with the GSIs there are again major concerns that
2022-01-06
As with the GSIs, there are again major concerns that GSM therapy in patients with symptomatic AD is almost certain to fail, unless the compound has additional mechanism of action not linked to Aβ that prove to beneficial [52]. Although Aβ1–42 or other longer Aβ peptides are critical for initiating
14856 records 424/991 page Previous Next First page 上5页 421422423424425 下5页 Last page